Network Intervention, a Method to Address Complex Therapeutic Strategies
暂无分享,去创建一个
Wei Zhou | Yong-Hua Wang | Dao-Gang Guan | Chi Zhang | Ai-Ping Lu | Yonghua Wang | Dao-Gang Guan | Chi Zhang | W. Zhou | A. Lu
[1] S. Kasif,et al. Network-Based Analysis of Affected Biological Processes in Type 2 Diabetes Models , 2007, PLoS genetics.
[2] P. Aloy,et al. A network medicine approach to human disease , 2009, FEBS letters.
[3] Doheon Lee,et al. Building the process-drug–side effect network to discover the relationship between biological Processes and side effects , 2011, BMC Bioinformatics.
[4] Derong Liu,et al. Data-Based Controllability and Observability Analysis of Linear Discrete-Time Systems , 2011, IEEE Transactions on Neural Networks.
[5] A. Barabasi,et al. Human disease classification in the postgenomic era: A complex systems approach to human pathobiology , 2007, Molecular systems biology.
[6] Thilo Gross,et al. Self-organized criticality as a fundamental property of neural systems , 2014, Front. Syst. Neurosci..
[7] Alan Talevi,et al. Multi-target pharmacology: possibilities and limitations of the “skeleton key approach” from a medicinal chemist perspective , 2015, Front. Pharmacol..
[8] Richard E. Neapolitan,et al. Discovering causal interactions using Bayesian network scoring and information gain , 2016, BMC Bioinformatics.
[9] J. Lehár,et al. Multi-target therapeutics: when the whole is greater than the sum of the parts. , 2007, Drug discovery today.
[10] P. Clemons,et al. Distinct Biological Network Properties between the Targets of Natural Products and Disease Genes , 2010, Journal of the American Chemical Society.
[11] M. Sen,et al. Wnt signalling in rheumatoid arthritis. , 2005, Rheumatology.
[12] C. Rosenberg. Contested Boundaries psychiatr y , disease , and diagnosis , 2006 .
[13] Henrik Madsen,et al. A New Reduced Rank Square Root Kalman Filter for Data Assimilation in Mathematical Models , 2003, International Conference on Computational Science.
[14] Chi Zhang,et al. Integration of chinese medicine with western medicine could lead to future medicine: molecular module medicine , 2016, Chinese Journal of Integrative Medicine.
[15] Balasubramaniam Natarajan,et al. Epidemic Threshold of an SIS Model in Dynamic Switching Networks , 2015, IEEE Transactions on Systems, Man, and Cybernetics: Systems.
[16] A. Barabasi,et al. Uncovering disease-disease relationships through the incomplete interactome , 2015, Science.
[17] E. Sorkin,et al. Enoxaparin , 2012, Drugs.
[18] Albert-László Barabási,et al. A Dynamic Network Approach for the Study of Human Phenotypes , 2009, PLoS Comput. Biol..
[19] E. Montgomery,et al. Classification and pathology. , 2008, The Surgical clinics of North America.
[20] Ulrik Brandes,et al. Biological Networks , 2013, Handbook of Graph Drawing and Visualization.
[21] A. Lu,et al. Current situation and progress in integrative medicine in China , 2008, Chinese journal of integrative medicine.
[22] Péter Csermely,et al. The efficiency of multi-target drugs: the network approach might help drug design. , 2004, Trends in pharmacological sciences.
[23] A. Barabasi,et al. Network medicine : a network-based approach to human disease , 2010 .
[24] Tero Aittokallio,et al. Network Pharmacology Strategies Toward Multi-Target Anticancer Therapies: From Computational Models to Experimental Design Principles , 2014, Current pharmaceutical design.
[25] Hideki Yamamoto,et al. Axin, a Negative Regulator of the Wnt Signaling Pathway, Directly Interacts with Adenomatous Polyposis Coli and Regulates the Stabilization of β-Catenin* , 1998, The Journal of Biological Chemistry.
[26] Raoul-Martin Memmesheimer,et al. Self-organized criticality in a model for developing neural networks , 2011, BMC Neuroscience.
[27] A. Giuliani,et al. Why so few drug targets: a mathematical explanation? , 2011, Current computer-aided drug design.
[28] W. Zhou,et al. Controllability and Observability of Fractional Linear Systems with Two Different Orders , 2014, TheScientificWorldJournal.
[29] S. Schreiber,et al. Target-oriented and diversity-oriented organic synthesis in drug discovery. , 2000, Science.
[30] Bin Yan,et al. CMGRN: a web server for constructing multilevel gene regulatory networks using ChIP-seq and gene expression data , 2014, Bioinform..
[31] Hans Clevers,et al. Wnt/β-Catenin Signaling in Development and Disease , 2006, Cell.
[32] A. Barabasi,et al. The human disease network , 2007, Proceedings of the National Academy of Sciences.
[33] D. Wernicke,et al. The expression of collagenase 3 (MMP-13) mRNA in the synovial tissue is associated with histopathologic type II synovitis in rheumatoid arthritis , 2006, Autoimmunity.
[34] H. Kubinyi. Drug research: myths, hype and reality , 2003, Nature Reviews Drug Discovery.
[35] Shengwu Xiong,et al. InDel marker detection by integration of multiple softwares using machine learning techniques , 2016, BMC Bioinformatics.
[36] P. Robinson. Classification and coding of rare diseases: overview of where we stand, rationale, why it matters and what it can change , 2012, Orphanet Journal of Rare Diseases.
[37] Thibault Liard,et al. A Kalman rank condition for the indirect controllability of coupled systems of linear operator groups , 2017, Math. Control. Signals Syst..
[38] Xia Jiang,et al. Learning Predictive Interactions Using Information Gain and Bayesian Network Scoring , 2015, PloS one.
[39] C. Rosenberg. Contested Boundaries: psychiatry, disease, and diagnosis , 2006, Perspectives in biology and medicine.